Omesan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omesan

Property Description
Active ingredient Omeprazole (or Omeprazole magnesium)
Form Enteric-coated capsules (Oral)
Pharmacological class Proton pump inhibitor (PPI)
Common use Reduction of gastric acidity (e.g., for severe heartburn)
Origin Synthetic substituted benzimidazole

Omesan is a medicinal entity that contains the active ingredient Omeprazole, and it is definitively classified as a foundational medicine in the Proton pump inhibitor (PPI) pharmacological class. This classifies it as a primary antiulcer agent. Omeprazole is a synthetic substituted benzimidazole derivative, a compound created to specifically interact with the acid-producing cells in the stomach.

The preparation is formulated as a single-ingredient medicine, with Omeprazole often present as the salt, Omeprazole magnesium. The product is most commonly administered via the oral route in the form of enteric-coated capsules. This enteric-coated design is essential and clinically recognized, as the Omeprazole active substance is highly susceptible to rapid degradation by stomach acid; the coating protects it until it can be reliably absorbed in the small intestine. This delayed-release characteristic is a key differentiating factor, guaranteeing a more effective systemic delivery compared to unprotected forms.


How Does the Omeprazole Class Work?

The Omeprazole class of medicines works by achieving a deep, sustained blockade of acid secretion within the stomach, which is its core general purpose, offering relief in scenarios like severe, frequent heartburn. This is accomplished through a highly specific action on the gastric parietal cells, the biological structures responsible for manufacturing and releasing acid.

Omeprazole provides a consistent therapeutic effect by targeting and permanently disabling the H^+K^+-ATPase enzyme—commonly known as the proton pump—which is the final step in acid production. This unique and decisive mechanism ensures that the acid secretion process is inhibited effectively, leading to significantly reduced gastric acidity. This mechanism of action is well-established, with its key role in acid management being recognized for its efficacy. The general benefit of this action is the creation of a non-corrosive environment within the upper gastrointestinal tract, which provides symptomatic relief and allows the stomach and esophageal linings to heal.

Regulatory References

  1. U.S. National Library of Medicine: MedlinePlus

What side effects are possible with Omesan?

Possible Side Effects and Safety Information: Omesan

The safety profile of Omesan (Omeprazole) is structured according to official regulatory classification systems, grouping documented adverse reactions by frequency and affected body system. The frequency framework defines effects as Common, Uncommon, Rare, Very Rare, or Not Known, based on reported incidence.

Officially Documented Adverse Reactions

The most frequently reported effects, classified as Common (ge 1/100 to < 1/10) in official labeling, primarily involve the Gastrointestinal System and Nervous System. These include headache, abdominal pain, diarrhea, flatulence, constipation, nausea, and vomiting. Less frequent effects, classified as Uncommon (ge 1/1,000 to < 1/100), cover reactions such as dizziness, insomnia, and rash.

Serious Safety Considerations

The regulatory profile explicitly lists serious adverse reactions that occur Rarely or Very Rarely (< 1/1,000). These include severe cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as severe blood disorders like agranulocytosis and systemic hypersensitivity reactions (anaphylaxis).

Population and Duration-Related Safety Patterns

Specific safety notes address the potential for certain effects to be associated with duration of use. Daily use for one year or more is officially associated with a potentially increased risk of bone fracture in the hip, wrist, or spine. Additionally, the regulatory label includes specific safety notes for individuals with Severe Hepatic Impairment, where the medicine's clearance may be slowed, and for older adults regarding the potential for drug interactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the overdose profile for Omesan (Omeprazole) based on reported high-dose ingestions, which were generally not associated with serious clinical outcomes.


Documented Overdose Manifestations

Reports of single oral doses up to 900 mg indicate that resulting symptoms were transient and typically mild. These documented manifestations affect several physiological systems:

  • Gastrointestinal: Nausea, vomiting, and abdominal pain.
  • Central Nervous System (CNS): Headache, confusion, and drowsiness.
  • General/Other: Tachycardia (increased heart rate), flushing, increased sweating, dry mouth, and blurred vision.

Required Emergency Actions

The regulatory guidance mandates specific actions if an overdose is suspected:

  • Immediate Action: Individuals must seek immediate medical attention for observation and supportive care.
  • Specific Antidote: Regulatory labeling explicitly states that no specific antidote for omeprazole overdosage is known.
  • Management: Treatment is strictly defined as symptomatic and supportive. The substance is extensively protein bound and is not readily dialyzable, meaning procedures like hemodialysis are not expected to be effective in removing the drug. The regulatory documents emphasize that no serious clinical outcome has been reported in these cases, supporting the focus on supportive monitoring.

Therapeutic Uses of Omesan

What Omesan Treats: Main Uses and Benefits

Omesan (Omeprazole) is applied across key therapeutic domains where addressing conditions related to increased acid activity is needed. Its primary function is to provide supportive relief and supports the body during periods of tissue irritation.

It is relevant in the management of conditions characterized by episodic or frequent symptoms arising from the backward flow of stomach acid, notably severe heartburn and acid regurgitation in Gastroesophageal Reflux Disease (GERD). The medication offers symptomatic relief that helps patients cope more steadily with difficult episodes. It is also used in the management of gastric and duodenal ulcers, and is applied in conditions involving erosive esophagitis.

It is also relevant for managing conditions with pathologically high acid output, such as Zollinger-Ellison Syndrome, and is used as supportive management for conditions involving H. pylori infection. This provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of tissue irritation.

Quick Fact: Relief for Persistent Heartburn The primary use is managing acid-related discomfort that is frequent or severe enough to create noticeable physiological strain, offering support to maintain functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Omesan (omeprazole) is generally indicated for adults and children over the age of one year for various conditions involving excess stomach acid. The specific formulation and dosage may differ for pediatric use compared to adults. Over-the-counter preparations are typically recommended only for adults aged 18 and older.


Contraindications and Precautions

Omesan should generally be avoided in individuals with a known hypersensitivity or allergic reaction to omeprazole or any other proton pump inhibitor (PPI) medication.

Caution and medical consultation are necessary if you have a history of certain health issues, including:

Condition Key Consideration
Severe Liver Disease May require dose adjustment due to slower drug metabolism.
Pregnancy/Breastfeeding Use only after a thorough discussion of risks and benefits with a healthcare provider.
Osteoporosis/Low Bone Density Long-term, high-dose use is associated with an increased risk of bone fractures (hip, wrist, spine).
Low Magnesium Levels (Hypomagnesemia) Prolonged use may exacerbate or cause low magnesium levels.

It is crucial to inform your healthcare provider about all current medications, as Omesan can interact with drugs such as atazanavir, nelfinavir, rilpivirine, and clopidogrel, potentially reducing their effectiveness or increasing adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Omesan (Omeprazole) has documented interaction patterns arising primarily from its roles as a pH modifier and an inhibitor of the CYP2C19 enzyme, as described in regulatory documents.

Formal Contraindicated Combinations

Co-administration is officially prohibited with the antivirals Nelfinavir and Rilpivirine. This restriction is documented because Omesan significantly decreases the plasma concentration of these medicines, which can diminish their therapeutic effect.

Pharmacokinetic and Exposure Interactions

Mechanism Interacting Substances Effect Documented in Regulatory Sources
CYP2C19 Inhibition Clopidogrel, Warfarin, Diazepam, Phenytoin Reduces the antiplatelet effect of Clopidogrel and decreases the clearance of Warfarin, Diazepam, and Phenytoin, increasing their systemic exposure.
Gastric pH Alteration Digoxin, Atazanavir, Iron Salts Increases the absorption and plasma concentration of Digoxin. Decreases the absorption and exposure of Atazanavir and Iron Salts.
Exposure Modifiers Voriconazole, Rifampicin, St. John's Wort Voriconazole increases Omesan's plasma levels. Rifampicin and the herbal product St. John's Wort decrease Omesan's plasma levels.

In patients with chronic liver disease, regulatory caution is noted due to reduced omeprazole clearance, which may intensify its interaction profile with other CYP-metabolized medicines. No mandatory time-separation rule in hours is specified in official labeling, but the pH interaction mechanism may necessitate separation for pH-dependent drugs.

Mechanism of Action

Irreversible Blockade of the H^+ K^+-ATPase Enzyme

Omesan is a pro-drug that undergoes acid-activated conversion within the highly acidic secretory canaliculi of the gastric parietal cells. The active metabolite forms a permanent covalent disulfide bond with accessible cysteine residues on the H^+ K^+-ATPase enzyme (Proton Pump), thus irreversibly disabling the pump's ability to transport hydrogen ions ( H^+) into the stomach lumen. This mechanism blocks the final pathway for acid secretion, regardless of the upstream stimulus.

Sustained Effect Determined by New Protein Synthesis

The irreversible nature of the bond dictates a sustained suppression of acid secretion. Full acid production only resumes when the parietal cells synthesize new H^+ K^+-ATPase enzymes. This reliance on enzyme turnover, rather than drug clearance, governs the prolonged duration of the drug’s physiological action, resulting in an elevated pH in the gastric contents.

Activity-Dependent Pathway Modulation

The drug’s action is activity-dependent, preferentially inhibiting only the proton pumps that are actively secreting acid (i.e., operating in a low- pH environment). Consequently, maximal physiological effect is achieved gradually, requiring repeated exposure over several days to ensure the majority of pumps, as they cycle into the active state, are successfully inhibited.

Dosage and Administration Information

Official Administration Guidelines for Omesan

This section outlines the procedural steps for using Omesan delayed-release oral capsules.


Dosing and Timing

  • Route of Administration: Oral.
  • Frequency: Once daily, taken at approximately the same time each day, preferably in the morning.
  • Timing with Meals: The dose must be taken at least one hour before a meal.
  • Adult Dosing (Example): A common recommended dose for adults is 20 mg once daily, though the prescribed dose may vary. The maximum recommended duration should not be exceeded without physician guidance.

Procedural Steps

Procedural Step Instruction/Rule
Preparation The delayed-release capsule must be swallowed whole with a glass of water.
Manipulation Do not chew, crush, or break the capsule or its pellets. This action may compromise the delayed-release properties of the medication.
Swallowing Difficulty If unable to swallow the capsule, open it and empty the pellets onto one tablespoon of soft, cool applesauce. Swallow this mixture immediately without chewing or crushing the pellets. Do not store the mixture for later use.

Missed Dose and Age-Specific Use

  • Missed Dose: If a dose is missed, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at the same time to make up for a missed one.
  • Pediatric Use: Administration rules and specific doses for children are based on body weight and must be strictly determined and managed by a physician.

Recent Clinical Evidence

Research evidence / Overview of Studies for Omesan

Evidence for Use in Acid Reflux and Esophagitis

Research into Omeprazole's use for acid-related symptoms has primarily involved short-term Randomized Controlled Trials (RCTs) and Systematic Reviews where it was evaluated against an inactive substance (placebo) and in studies including other acid-reducing medicines as a comparator. These studies focused on adult populations experiencing severe heartburn and acid regurgitation, which are outcomes related to physical discomfort in conditions like Gastroesophageal Reflux Disease (GERD). Research examined how symptoms evolved in the observed populations during the short treatment periods, typically 4 to 8 weeks.

For erosive esophagitis—a condition involving tissue irritation—controlled RCTs were applied to adult populations. The main outcomes studied were the measurements of mucosal healing, confirmed by endoscopy. These studies reported patterns related to changes in visible damage to the esophageal lining over scheduled follow-up visits. Follow-up durations were limited in many initial trials evaluating responses, meaning long-term outcomes for continuous symptom control are not as fully established by RCTs.


Evidence for Use in Peptic Ulcer Disease and H. pylori Management

Omeprazole was evaluated in research exploring Peptic Ulcer Disease (PUD). Studies examined endoscopic measurements related to ulcer healing as a key outcome, often comparing results against other ulcer treatments. Findings reported in these studies described patterns observed in measurements related to tissue repair over short-term intervals (e.g., 2 to 8 weeks). Research also explored the longer-term scenarios related to the prevention of ulcer recurrence in the observed populations.

For conditions involving H. pylori bacteria, Omeprazole was used and studied as a component of multi-drug combination regimens with specific antibiotics. Trials focused on the key outcome of pathogen eradication rates—measuring whether the bacteria was successfully eliminated from the body. Data show patterns related to the rate of pathogen elimination, which may vary geographically due to local variations in bacterial resistance to the co-administered antibiotics.


Evidence in Special Populations

Omeprazole was studied for use in children (typically ge 1 year of age) experiencing GERD and erosive esophagitis. These studies evaluated outcomes related to measuring changes in symptom severity and the status of tissue irritation in the pediatric population. Findings describe patterns related to how symptoms evolved in the observed pediatric populations.

Research has also explored populations with conditions presenting with cycles of stability and flare-ups, such as ulcers due to continuous use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Studies monitored outcomes related to ulcer development and the status of tissue repair in these specific groups. The results apply only to the populations studied, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. National Library of Medicine (NLM) Drug Record: Omeprazole
  2. National Institute for Health and Care Excellence (NICE) Guideline: Gastro-oesophageal reflux disease and dyspepsia in adults

Frequently Asked Questions (FAQ)

Common questions about Omesan (FAQ)

Q: Can Omesan affect how other prescription medications are absorbed in the body?

A: Yes, Omesan can affect the absorption of certain other medicines because it significantly lowers the level of acid in the stomach. Official documents indicate that this change in stomach pH can interfere with the way specific medicines are absorbed. This may reduce the effectiveness of some drugs or increase the effects of others. Discussing all current medicines with a healthcare provider helps manage potential interaction risks.

Q: Has Omesan been studied in pregnant women, and what does the evidence indicate?

A: Official regulatory information notes that there are no adequate and well-controlled studies specifically in pregnant women. While official regulatory documents advise caution, research data generally indicate omeprazole is not associated with a major increase in the overall risk of birth defects. Use during pregnancy should only happen after a careful evaluation of the potential benefits and risks by a healthcare provider.

Q: Does Omesan cause stomach pain, or is that a symptom of the condition it treats?

A: Both are possible, according to official information. Regulatory documents list abdominal pain as one of the most common adverse reactions reported with Omesan use. However, Omesan is prescribed to treat conditions that cause stomach pain, and a symptomatic response to therapy does not rule out a more serious underlying issue. If abdominal pain persists or worsens, this is a signal to consult with a healthcare professional.

Q: What if the symptoms Omesan is treating get worse after starting the medication?

A: Official warnings state that a symptomatic response to Omesan therapy does not exclude the presence of a serious underlying condition. If a person experiences worsening symptoms or an early relapse after treatment, regulatory guidance indicates that this situation warrants an evaluation for additional diagnostic testing and follow-up by a healthcare professional.

Q: Why is Omesan sometimes prescribed along with certain antibiotics?

A: Omesan is officially indicated and studied as a necessary component of multi-drug combination regimens, typically with specific antibiotics like amoxicillin and clarithromycin. This combination is prescribed for the specific purpose of eradicating the Helicobacter pylori bacterium, which is a common cause of stomach and duodenal ulcers.

Q: Is the tiredness or fatigue experienced while taking Omesan a known common side effect?

A: Regulatory labeling lists drowsiness (somnolence) and fatigue (asthenia) as reported effects classified as Common or Uncommon in some populations. However, if unusual tiredness or weakness persists, a review with a healthcare provider is appropriate, as these symptoms can also be associated with other documented conditions like hypomagnesemia (low magnesium).

Q: Can Omesan cause any changes in skin sensitivity, like an increased risk of sunburn?

A: Official regulatory information notes that reactions involving the skin are possible with Omesan. This includes reports of increased sensitivity of the skin to sunlight (photosensitivity), as well as skin redness and other discolorations. Because increased sensitivity to sunlight has been documented, individuals may wish to consider sun protection while using this medicine.

Q: Is Omesan associated with any risk of developing a form of lupus?

A: Official regulatory warnings state that the use of PPIs like Omesan may be associated with the new onset or exacerbation of Cutaneous (skin-based) and Systemic Lupus Erythematosus ( lupus). If lupus is suspected, official guidance recommends that the medicine should be discontinued under the direction of a medical professional.

Q: Do studies suggest Omesan has different effects based on age or gender?

A: Official drug documents contain specific recommendations and data for pediatric use (children) and specific warnings for older adults regarding factors like drug interactions or the risk of bone fracture. However, regulatory documents do not generally specify differences in the drug's core effects based on gender.

Q: Can Omesan be used for long-term treatment, or is it only for short periods?

A: Omesan is indicated for short-term courses, typically 4 to 8 weeks, for common conditions like ulcers and erosive esophagitis. However, official documents confirm it is also indicated for the long-term treatment of certain pathological hypersecretory conditions in adults, such as Zollinger-Ellison Syndrome.

Q: Can taking Omesan affect the body's magnesium levels?

A: Yes, regulatory warnings indicate that Omesan use is associated with hypomagnesemia ( low magnesium levels), which is reported rarely with prolonged treatment (usually one year or longer). Low magnesium can be serious, and the potential need for monitoring magnesium levels for continuous use should be discussed with a healthcare provider.

Q: Is Omesan only used for acid reflux, or are there other approved uses?

A: Omesan is officially approved for several uses beyond just acid reflux (GERD). These indications include treating active duodenal and gastric ulcers, managing erosive esophagitis, eradicating H. pylori bacteria, and long-term treatment of pathological hypersecretory conditions.

Q: Is the effect of Omesan immediate, or does it build up in the system over days?

A: The medicine's effect begins quickly, often within one hour of taking the capsule. However, official documents state that the full inhibitory effect on acid secretion is gradual, and the maximum, sustained benefit typically reaches a plateau after four days of repeated once-daily dosing.

Q: What happens if I accidentally miss a dose of Omesan?

A: Official regulatory instructions advise that if you miss a dose, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, you must skip the missed dose and resume your regular schedule. You must never take two doses at the same time.

Q: Can Omesan be crushed or opened for people who have trouble swallowing pills?

A: Official administration instructions strictly state that you must not chew, crush, or break the capsule because it contains enteric-coated pellets that are destroyed by stomach acid. If you have trouble swallowing, the guidance is to open the capsule and mix the pellets onto a tablespoon of soft, cool applesauce, which must then be swallowed immediately.

Q: Can Omesan be used in combination with antacids for breakthrough symptoms?

A: While Omesan and antacids work differently—Omesan stops acid production and antacids provide immediate relief—many formulations of omeprazole have been studied in combination with antacids. If breakthrough symptoms occur frequently, it is helpful to discuss the appropriate management strategy, which may include the combined use of these medicines, with a healthcare professional.

Q: Is there a maximum length of time Omesan is recommended for non-prescription use?

A: For non-prescription (over-the-counter) use, Omesan is indicated only for a 14-day course of treatment. Regulatory labeling specifies not to take it for more than 14 days or more often than every 4 months. The label notes that extended use should only occur under the direction of a healthcare professional.

Q: Can Omesan change the results of any routine blood tests?

A: Yes, regulatory documents indicate that Omesan may interfere with certain blood tests. By increasing the pH (reducing acid) in the stomach, it can cause elevated levels of a substance called Chromogranin A (CgA), which may interfere with diagnostic tests for neuroendocrine tumors.

Q: Do I need to take Omesan with a full glass of water, or can it be with a small sip?

A: Official administration instructions recommend swallowing the capsule whole with a glass of water. This helps ensure the capsule passes into the stomach and small intestine correctly and that the medicine's protective coating remains intact for proper absorption.

Q: Is Omesan known to interact with any common heart or blood pressure medications?

A: Official interaction tables list several heart and blood-related medicines that may interact with Omeprazole. These include Clopidogrel and Warfarin (blood thinners), as well as Digoxin (a heart medicine). Taking Omesan with these medicines may change the exposure of those drugs, which is a consideration for healthcare providers when managing treatment.

Q: What are the signs of a serious side effect that would require immediate attention while on Omesan?

A: Official warnings describe symptoms associated with serious, though rare, adverse reactions. These include signs of Severe Cutaneous Reactions like painful, peeling, or blistering skin (such as Stevens-Johnson syndrome). They also include signs of Acute Interstitial Nephritis, which involves a decrease in urine or blood in the urine.

Q: Are there specific symptoms that mean Omesan is not the right medication?

A: Yes, regulatory information for non-prescription use lists specific red-flag symptoms that suggest a more serious condition is present, meaning Omesan should not be used without a doctor's guidance. These include trouble or pain swallowing food, vomiting with blood, bloody or black stools, or heartburn with lightheadedness or sweating.

Q: How does Omesan affect the balance of bacteria in the gut?

A: Regulatory warnings mention that PPI therapy like Omesan may be associated with an increased risk of Clostridium difficile-associated diarrhea. This type of diarrhea is caused by changes in the gut environment that allow this specific germ to overgrow. This association is often seen in hospitalized patients.

Q: What is Omesan's safety classification for women who are breastfeeding?

A: Official regulatory documents indicate that Omeprazole is excreted in human milk. Due to the presence of omeprazole in human milk, the decision regarding the drug's use during lactation should be made by a healthcare provider after weighing the importance of the drug to the mother against any potential risk to the breastfed child.

Q: Are there any known issues with taking Omesan if a person has kidney problems?

A: Official warnings note that a type of kidney problem called Acute Tubulointerstitial Nephritis ( TIN) has been observed in patients taking PPIs. If this condition is suspected, regulatory guidance states the medicine requires discontinuation and the patient requires evaluation by a medical professional.

Q: Are there any known long-term expectations for people who use Omesan continuously?

A: For continuous, long-term use (e.g., a year or longer), regulatory documents note patterns such as an increased risk of bone fracture, potential Vitamin B-12 deficiency, low magnesium levels, and the development of benign growths called fundic gland polyps.

How should Omesan be stored and disposed of?

How to Store and Dispose of Omesan

To maintain the stability and effectiveness of Omesan (Omeprazole), strict storage and handling conditions must be followed as detailed in official regulatory labeling.


Storage and Stability Requirements

Condition Regulatory Requirement
Temperature Store at a temperature not exceeding 30°C.
Protection Store in a dry place and protect from light.
Packaging Keep the medicine in the original package; bottles must be kept tightly closed.
In-Use Shelf Life Once an HDPE bottle is opened, store below 25°C and use within 100 days.

Handling and Disposal

The product must be kept out of the sight and reach of children. Unused or expired Omesan, as well as any related waste material, must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omesan found in:

A-Z Index: